HAVCR2 and neoplasm: TIM-3 and PD-1 co-blockades significantly inhibited tumor growth and prolonged the survival time of ID8VEGF-bearing mice with HPD during anti-PD-1 treatment compared to anti-PD-1 monotherapy (Fig. 2B, C).